Preclinical applications: gastrointestinal research
Embracing inter-individual variation at the preclinical stage is key to de-risking clinical trials. The SIFR® leverages high throughput and validated predictivity to map such variation and further decipher the mechanism of action of products.
Pieter Van den Abbeele, CSO Cryptobiotix
- Screen candidates for desired features
- Characterise your ingredient & generate evidence during your product development cycle to move to the next step
- Generate and protect your IP by identifying a set of significant features of your product
- Support your claims with mechanistic information
A tailored preclinical approach for your research needs
Screening and in-depth characterisation of actives – Whether you are at an early R&D stage with no clear lead candidate or you need to generate robust data on the mechanism of action of your actives, Cryptobiotix’s technologies will address your research questions at the suitable depth. Allocate your budget wisely by screening candidates in a time- and cost-effective manner, before diving into your lead candidates with advanced analytics.
Always consider interindividual variability – Each individual’s gut microbiota has a unique signature and will interact with your products in different ways. Do not wait for the clinical trial, de-risk your product development early by acknowledging and investigating the homogeneity or heterogeneity of this interplay early on. Do not use pooled faecal microbiota, investigate each individuals separately. Not only do you not need to anymore thanks to the throughput of the SIFR® technology, but you will also create a artificial community with excessively high taxonomic and functional diversity, not representative of any real-world individual.
Innovate through synergies between products – Many one-ingredient products have been investigated over the past years. Aside of novel approaches and molecules, innovation comes from finding synergies in products combinations. As an example, synbiotics combine the best of prebiotics and probiotics or live biotherapeutic products (LBP). Or perhaps you can support the recovery of the microbiome by combining an active pharmaceutical ingredient (API) with some prebiotic fibres. A quick, meaningful SIFR® screening across combinations of actives will bring you a step further to your next lead candidate.
Optimal dosing – Which minimal dose of product would exert a significant impact on the microbiota? Or how to connect the preclinical dosing to the in vivo situation? The answer is not trivial, but we can help you with that as well.
Expertise in your field of research: functional foods & therapeutics
Functional food
Prebiotics, HMOs, polyphenols
Probiotics
Synbiotics
Postbiotics
Fermented food
Plant extracts
…
Therapeutics
Active pharmaceutical ingredients (API)
Live biotherapeutic products (LBP)
Faecal matter transplant (FMT)
…
A wide range of model organisms and health conditions
Human or animal – The SIFR® technology can be applied for human as well as monogastric animal simulations. Furthermore, physiological, microbiological and dietary components can be modulated to simulate various age groups, such as infants, toddlers or adults. Aside of the traditional ‘healthy’ population, the SIFR technology can be adapted to investigate a spectrum of dysbiotic and pathogenic conditions.
